ArticleThorax2006
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Article in Thorax, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 40 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma
A Proof-of-concept Study to Evaluate the Benefit From add-on Therapy With Montelukast Versus Salmeterol in Children With Asthma Carrying the Arg/Arg-16 beta2-receptor Genotype
Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma
Who cites it
40 citing papers in PubMed, 6 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- ADRB2 haplotypes and asthma exacerbations in children and young adults: An individual participant data meta-analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Pooled it
- Genome-wide association studies of exacerbations in children using long-acting beta2-agonists.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2021Pooled it
- Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation.The pharmacogenomics journal · 2020Pooled it
- Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment.The Journal of allergy and clinical immunology · 2016Pooled it
- ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2015Pooled it
- Pooled it
- Trial
- Trial
- Effect of the Arg16Gly βAllergy · 2026Article
- The Predictive Role of Biomarkers and Genetics in Childhood Asthma Exacerbations.International journal of molecular sciences · 2021Review
- LTA4H rs2660845 association with montelukast response in early and late-onset asthma.PloS one · 2021Article
- Activation of βArchives of pharmacal research · 2021Review
- Barriers to achieving asthma control in adults: evidence for the role of tiotropium in current management strategies.Therapeutics and clinical risk management · 2019Review
- How does race and ethnicity effect the precision treatment of asthma?Expert review of precision medicine and drug development · 2019Article
- Association of genetic variants with level of asthma control in the Arab population.Journal of asthma and allergy · 2019Article
- Article
- Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium.Pharmacogenomics · 2017Article
- The evidence on tiotropium bromide in asthma: from the rationale to the bedside.Multidisciplinary respiratory medicine · 2017Review
- βHandbook of experimental pharmacology · 2017Review
- Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.Paediatric drugs · 2016Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe homozygous presence of the arginine-16 variant of the beta(2) adrenoceptor gene ADRB2 reverses the benefits from the regular use of short acting beta(2) agonists in asthmatic adults compared with the homozygous glycine-16 genotype. We studied the effect of this polymorphic variation on asthma exacerbations in children and young adults and its relation to long acting beta(2) agonists.
methodsA cross-sectional survey was undertaken using electronic records, direct interviews, and genotype determination of position 16 and 27 of the ADRB2 gene in DNA from mouthwash samples of 546 children and young asthmatics attending paediatric and young adult asthma clinics in Tayside, Scotland during 2004-5. The primary outcome measure was asthma exacerbations over the previous 6 months.
resultsThere was an increased hazard of asthma exacerbations across all treatment steps of the British Thoracic Society (BTS) asthma guidelines when the homozygous genotypes Arg/Arg and Gly/Gly were compared (OR 2.05, 95% CI 1.19 to 3.53, p = 0.010), particularly in patients treated with salmeterol (OR 3.40, 95% CI 1.19 to 9.40, p = 0.022). The Glu27Gln polymorphism had no significant effect on asthma exacerbations in any treatment group.
conclusionsThe arginine-16 genotype of ADRB2 predisposes to exacerbations in asthmatic children and young adults, particularly in those exposed to regular salmeterol. This may be explained by genotype selective salmeterol induced downregulation and impaired receptor coupling, and associated subsensitivity of the response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.